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Summary: Ongoing studies investigating fracture healing have
uncovered and allowed investigators to gain a better understanding of
where the variety of cells, which participate in this process, originate,
and how they communicate as well as how they can be enhanced to
successfully heal a fracture when the process has slowed or failed
completely. This brief review will highlight some of the recent findings
regarding the role the immune system in fracture healing and how these
cells communicate with each other during the healing process. In
addition, two 2 methods that have recently been shown to be promising
techniques in supporting fracture when it stalls or reversing the process,
when the fracture has failed to heal, will also be described.
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OSTEOIMMUNOLOGY
There is increasing awareness that the immune system
and the skeletal system are intricately linked. The term “os-
teoimmunology” was coined in 2000 by Arron and Choi1 to
describe this field of study.
Achieving fracture union is dependent on the initial
inflammatory phase as the early signaling cascades initiated play
a critical role in triggering osseous repair. Both local inflamma-
tion and systemic inflammation, mediated by the immune
system, play an important role in the activities of osteoblasts
and osteoclasts, which affects downstream fracture healing.
The local factors in the initial inflammatory response to
fracture include: (1) associated soft-tissue injury, (2) milieu of
the fracture hematoma, and (3) early biomechanical stability
of the fracture. With extensive local soft-tissue trauma, early
fracture healing can be impaired as a result of local blood
supply disruption, impaired neutrophil migration to the
fracture site, and decreased presence of muscle-derived
osteoprogenitor cells.
The early fracture hematomas consist mainly of infil-
trated inflammatory cells, which are responsible for regulating
local inflammation, and play a very important role in fracture
healing (Fig. 1). The acute hematoma is an acidic and hypoxic
environment, and this milieu promotes the initiation of a local
inflammatory cascade, beginning with the release of proin-
flammatory cytokines and angiogenic factors.
In addition, the initial vascular and inflammatory
response to injury is highly sensitive to mechanical stability
and affects osteogenesis. Early stabilization of fractures
promotes early vascular response to injury and revasculari-
zation throughout the course of fracture repair.2
The systemic factors that influence this initial inflam-
matory response to fracture include the following: (1) acutely
elevated systemic inflammation (ie, multiple injuries), (2)
chronically elevated systemic inflammation (ie, rheumatoid
arthritis and diabetes), and (3) systemic anti-inflammatories
(ie, nonsteroidal anti-inflammatories).
Patients with multiple fractures exhibit acutely elevated
systemic inflammation, concomitant delayed fracture healing,
and increased risk for nonunion.3 Although neutrophils are
vital for early response to injury, neutrophils remain upregu-
lated and primed for up to 2 weeks after major trauma. Pro-
longed neutrophil presence at the site of fracture hematoma
has been implicated in delayed fracture healing.4
Chronic inflammatory diseases, such as in diabetes
mellitus and rheumatoid arthritis, may cause impaired fracture
healing due to factors which increases osteoclastogenesis.5
Achieving fracture union is paramount for orthopaedic
surgeons; therefore, understanding the interplay between the
immune system and the skeletal system is important. It is
becoming increasingly apparent that each step along the
pathway of providing fracture care can have an impact on
fracture union.6 Strategies surgeons should implement for
promoting fracture healing should include the following: real-
izing the importance of preserving fracture hematoma and the
soft tissues about the fracture, providing early fracture stabil-
ity, minimizing systemic inflammatory response to injury, and
optimizing host chronic inflammatory disease states, which
often requires a multidisciplinary approach.
CELL-TO-CELL COMMUNICATION AND THE
ROLE OF EXTRACELLULAR VESICLES
Although bones possess excellent regenerative prop-
erties and most fractures heal uneventfully, approximately
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5%–10% of fractures are complicated by delayed healing or
nonunion.7 Fracture healing is a complex process, regulated
by many genes and cell types and influenced by cytokines,
chemokines, growth factors, and other molecules. The inter-
cellular communications between cells are important and
can occur through either adhesion or direct interactions to
transmit signals and modulate physiologic activities or
through soluble mediators. Recent studies demonstrated that
extracellular vesicles (EVs) also can act as mediators in
intercellular communications.8 EVs are membranous
vesicles, which are distinguished from one another by sub-
cellular origin, size, content, and the formation mechanism.
Three types of EVs are known: exosomes, shedding micro-
vesicles, and apoptotic bodies.9 Exosomes are cup-shaped
membranous EVs, with a diameter of 30–100 nm. Shedding
microvesicles are generated by blebbing and shedding of the
plasma membrane from almost all cell types (dia. 100–1000
nm); apoptotic bodies are membrane vesicles generated by
apoptotic or dying cells (dia. 50–5000 nm).
EVs carry several kinds of molecular constituents
(cargoes) of their cell of origin such as proteins, RNA, DNA,
and lipids, and membrane-bound molecules at their surface.10
EVs also contain proteins related to osteoclast differentiation,
such as RANKL and RANK.11 Furthermore, a number of
bone-related microRNAs (miRNAs) have been found to play
an important role in osteoblastic differentiation.12
The emerging role of EVs in bone remodeling during
physiologic and pathologic conditions has been highlighted in
a number of recent studies and reviews.13 It has been shown
that during fracture healing, osteoblasts directly communicate
with osteoclasts, bone marrow aspiration concentrates
(BMACs), and others through EVs. During early phases of
fracture healing (coagulation and inflammatory), the activa-
tion of platelets, neutrophils, and macrophages play essential
roles.14 A short time after blood vessel and tissue injury,
procoagulatory platelet-derived EVs are released, which acti-
vate and attract neutrophils and macrophages. The activation
of neutrophils, in turn, results in secretion of neutrophil EVs
that contribute to increase of the inflammatory response. EVs
from BMACs and chondrocytes have been shown to release
multiple growth factors, providing a microenvironment con-
ducive for angiogenesis and tissue regeneration.
Various approaches have been developed to enhance
fracture healing, including the use of osteogenic materials
(bone marrow grafting and injection of active substance),
tissue engineering, and stem cell transplantation. These
observations open the possibility to use EVs in tissue
engineering. The biological characteristics and particular
structure of EVs make their use an appealing strategy for
tissue regeneration. This novel strategy resolves the problems
of immunogenicity and toxicity because BMACs-derived
exosomes maintain the immune privileged properties of their
cell of origin.
The continuing research on the role of EVs in the
fracture-healing process could deliver essential information
for improving the treatment of bone fractures. Nevertheless,
further studies are necessary before stem cell–released EVs
can be developed into a practical and effective therapeutic
tool.
CELL THERAPY FOR PREVENTION OF DELAYED
FRACTURE UNION
Early, painless, and expedite return to function are the
goals when treating long bone fractures. In the lower
extremity, significant paradigm shift occurred with the
development of reamed, locked nailing of femoral and tibial
fractures.15 However, the incidence of delayed and nonunion,
especially in tibial diaphyseal and distal metaphyseal frac-
tures, has been reported to be as high as 33%.16 Recently,
biological treatments such as BMAC, and systemic metabolic
agents have been investigated as to their ability to facilitate
fracture healing.17
Risk factors have been identified for impaired fracture
healing, and these include fracture morphology, comminution,
and the presence of an open fracture. Other host factors such as
diabetes, smoking, alcohol consumption, and medical comor-
bidities have also been associated with the risk of delayed
union/nonunion. Newer assessment tools, such the radio-
graphic union scale in tibial (RUST) fractures score and the
use of computerized tomography, have significantly increased
the ability to more objectively assess fracture healing.18
MINIMALLY INVASIVE
BIOLOGICAL INTERVENTIONS
When either delayed union or nonunion is diagnosed,
several minimally invasive interventional options are
FIGURE 1. The importance of the fracture hematoma in
immune mediation of angiogenesis and fracture healing.
Inflammatory cytokines include tumor necrosis factor—alpha
(TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-
11 (IL-11), interleukin-18 (IL-18), and monocyte chemo-
attractant protein-1 (MCP-1). Macrophages produce trans-
forming growth factor—beta (TGF-b) and platelet-derived
growth factor (PDGF) and the vascular endothelial growth
factor (VEGF) and PDGF released by the mast cells recruited to
the fracture hematoma all interact in concert to promote local
angiogenesis and downstream osteogenesis.
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available. Bone marrow aspirate injection into a nonunion has
had some degree of success in the past.19 A breakthrough was
made with the discovery of the mesenchymal stem cell (MSC)
and their osteogenic potential.20 These MSCs are found in
bone marrow as well as other tissues and are identified by
the presence of certain surface antigens. BMAC injections
have been investigated previously to assess this techniques
effectiveness in supporting healing.17
Although cells are the essential osteoinductive compo-
nent of fracture healing, other elements are also involved in
the process, including growth factors and matrix proteins.
Therefore, a combination of cells, growth factors, scaffold
proteins, and a stable mechanical environment (“diamond
concept”) is believed to be crucial for supporting unimpaired
fracture healing.21
After reviewing the risks of developing a nonunion and
its considerable consequences, we raised the question of
whether early, minimally invasive intervention could prevent
the development of a nonunion in “at-risk” fractures.
The risk for nonunion of distal diaphyseal tibial
fractures has been estimated between 6% and 33%. Therefore,
it seemed logical to reduce this risk by early, prophylactic
intervention for these fractures. Therefore, we conducted
a randomized, prospective study, of an early intervention of
distal tibia fractures consisting of injecting MSCs (CD105+)
in conjunction with demineralized bone matrix (DBM) and
platelet-rich plasma (PRP) into the fracture site in an effort to
prevent the development of a nonunion.22 The treatment
group underwent bone marrow and peripheral blood aspira-
tion. Separation of MSCs from the bone marrow aspirate was
performed based on the CD105+ antigen. The separation pro-
cess resulted in the acquisition of a nearly pure MSC sub-
population, these MSCs were mixed with PRP, and the MSC/
PRP mixture was then mixed with DBM and injected into the
fracture site. At 1 year postoperatively, all fractures healed.
However, in the control group, there were 3 cases of delayed
union. The most encouraging finding was the significant
reduction in mean time to union from 4.0 months in the
control group to 2.2 months in the treatment group (P ,
0.03). Figure 2 represents a typical case comparison between
the 2 groups.
Fracture nonunion is a serious consequence of many
long bone fractures. Every effort should be made to prevent
the occurrence of nonunion. Controllable factors are mainly
good surgical technique and providing an adequate biological
and mechanical environment for the fracture to heal. How-
ever, prompt identification of fractures at risk of developing
into a delayed or nonunion will permit minimally invasive
procedures to be used that could reverse the pathway of
impaired fractured healing.
BONE MARROW ASPIRATE CONCENTRATE FOR
FRACTURES AND NONUNIONS
Osteogenic cellular therapies are being developed to
include autologous harvesting, cellular concentration, and
point of service delivery in the operating room. This
technology provides osteogenic material that can be used to
stimulate fracture and nonunion healing.
The critical component necessary to promote fracture
healing is to provide viable osteoprogenitor cells. Bone
marrow is a plentiful source of musculoskeletal stem cells,
which can also be found in periosteum, cartilage, muscle, fat,
and vascular pericytes.23 However, there is a paucity of os-
teoprogenitor cells present in the mature marrow aspirate.24
Osseous regeneration is dependent on the number of cells
available to participate in bone synthesis.
Hernigou et al reported on patients treated for a non-
infected nonunion who had undergone bone marrow aspira-
tion from both iliac crests.25 He demonstrated complete
healing in 53 of 60 patients. Those patients who healed had
.1500 progenitors/cm3 while those patients who did heal all
had lower numbers and concentrations of colony-forming
units.
The aspiration technique is very specific to maximize
the number of effective progenitor cells per unit volume.
Muschler et al26 determined that no more than 2 mL of blood
should be aspirated from any single area in the iliac crest to
avoid dilution with peripheral blood. In addition, these trans-
planted cells must have the appropriate substrate to become
attached to once the cells have been implanted at the injury
site.
The concept of composite grafts combining marrow
elements with other osteoconductive and/or osteoinductive
substrates has become a major area of investigation. Loading
these cells onto an osteoconductive substrate provides the
cells with a stable and subsequently well-vascularized
environment. In this environment most of these cells will
differentiate into osteoblasts.27–29
FIGURE 2. Lateral radiographic views of distal tibial fractures
fixed with an intramedullary nails. A, Lateral radiograph of
a control group patient at 6 months postoperatively, dem-
onstrating still evident fracture gap of the anterior cortex. B,
Lateral radiograph of a treatment group patient at 3 months
postoperatively showing cortical bridging of both anterior and
posterior cortices, abundant callus formation and disappear-
ance of the fracture gap.
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Collagen sponges, hydroxyapatite substrates, and other
porous ceramics, as well as particulate DBM have all been
used in combination with BMAC to fabricate “composite
grafts” (Fig. 3).
Contemporary clinical series have demonstrated excel-
lent results when the above factors have been attended to in
the treatment of long bone nonunions. Unfortunately, these
combination grafts not enjoyed widespread use. This may be
due to (1) the variability resulting from inconsistent and
incorrect aspiration techniques and faulty instrumentation
necessary to achieve consistent aspirates, (2) low osteopro-
genitor content of these insufficient aspirates, and (3) the
combination of these aspirates with suboptimal scaffolding
materials.
Studies that use correct aspiration and concentration
methodologies as well as adhere to using appropriate
documented composite grafting techniques do demonstrate
the value of marrow aspirates for graft substitution. The
efficacy of this technique is related to the number of
progenitors cells present in the graft mixture, and highlights
the need to concentrate the aspirates and achieve the baseline
number of cells necessary to achieve osteogenesis.
CONCLUSIONS
Fracture healing is a highly complex and regimented
process. It is now understood that process includes the body’s
immune system and a complex manner by which the cells
participating in fracture healing communicate. Recognizing
fractures early on that are not likely to heal or have not
healed, allows for interventions, including the use of the
body’s own osteoprogenitor cells and growth factors with
the addition supportive substrates, to stimulate complete
healing, thus saving the patient from the considerable mor-
bidity associated with nonunion.
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